Your browser doesn't support javascript.
loading
Peripherally inserted central catheters (PICCs) in cancer patients under chemotherapy: A prospective study on the incidence of complications and overall failures.
Bertoglio, Sergio; Faccini, Beatrice; Lalli, Luca; Cafiero, Ferdinando; Bruzzi, Paolo.
Afiliación
  • Bertoglio S; Department of Surgical Sciences (DISC), University of Genova, Genova, Italy.
  • Faccini B; Genova-Italy Unit, Department of Surgery, IRRCS San Martino IST-National Institute for Cancer Research, Genova, Italy.
  • Lalli L; Health Nursing Office, IRRCS San Martino-IST National Institute for Cancer Research, Genova, Italy.
  • Cafiero F; Clinical Epidemiology Unit, IRRCS San Martino-IST National Institute for Cancer Research, Genova, Italy.
  • Bruzzi P; Genova-Italy Unit, Department of Surgery, IRRCS San Martino IST-National Institute for Cancer Research, Genova, Italy.
J Surg Oncol ; 113(6): 708-14, 2016 May.
Article en En | MEDLINE | ID: mdl-27020965
BACKGROUND AND OBJECTIVES: The increasing use of peripherally inserted central venous catheters (PICCs) for chemotherapy has led to the observation of an elevated risk of complications and failures. This study investigates PICC failures in cancer patients. METHODS: A prospective study was conducted at a single cancer institution on 291 PICC placement for chemotherapy. The primary study outcome was PICC failure. RESULTS: Median follow-up was 119 days. PICC complications occurred in 72 patients (24.7%) and failures with removal in 44 (15.1%). Reasons for failures were upper extremity deep venous thrombosis (UEDVT) 12 (4.1%), central line associate bloodstream infection (CLABSI) 5 (1.7%) with an infection rate of 0.95 per 1,000 catheter days, exit site infection 9 (3.1%) with a rate of 1.46 per 1,000 catheter days, catheter dislodgment 11 (3.8%), and occlusion 7 (2.4%). Statistically significant risk factors were previous DVT (HR 2.95, 95%CI 1.33-6.53), reason for PICC implant (HR 3.65, 95%CI 1.12-10.34) and 5-fluorouracil, oxaliplatin and bevacizumab based chemotherapy (HR 3.11, 95%CI 1.17-8.26). CONCLUSIONS: PICC is a safe venous device for chemotherapy delivery. Nevertheless, a 15% rate of failure has to be taken in account when planning PICC insertion for chemotherapy purposes. J. Surg. Oncol. 2016;113:708-714. © 2016 Wiley Periodicals, Inc.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cateterismo Venoso Central / Cateterismo Periférico / Protocolos de Quimioterapia Combinada Antineoplásica / Falla de Equipo / Infecciones Relacionadas con Catéteres / Catéteres Venosos Centrales / Neoplasias Tipo de estudio: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Surg Oncol Año: 2016 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cateterismo Venoso Central / Cateterismo Periférico / Protocolos de Quimioterapia Combinada Antineoplásica / Falla de Equipo / Infecciones Relacionadas con Catéteres / Catéteres Venosos Centrales / Neoplasias Tipo de estudio: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Surg Oncol Año: 2016 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Estados Unidos